Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1986 Oct;66(1):173–180.

Circulating thymic hormone activity in young cancer patients.

R Consolini, B Cei, P Cini, E Bottone, L Casarosa
PMCID: PMC1542647  PMID: 3802571

Abstract

We measured serum levels of Facteur Thymique Sérique (FTS) in 56 young cancer patients compared to normal controls. All patients who received immunosuppressive therapy had low age-corrected titres of FTS. Low levels were also found at diagnosis and off therapy. Plasma from 22 patients contained factors capable of inhibiting biological activity of FTS in vitro. The nature of this inhibitor has not been elucidated. No zinc deficiency was found in the patients studied, suggesting that FTS is secreted in its active form. Our study points out the importance of monitoring FTS activity in young cancer patients for its implications on immunological surveillance. The practical applications of thymic hormone therapy in cancer patients are discussed.

Full text

PDF
173

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Atkinson K., Incefy G. S., Storb R., Sullivan K. M., Iwata T., Dardenne M., Ochs H. D., Good R. A., Thomas E. D. Low serum thymic hormone levels in patients with chronic graft-versus-host disease. Blood. 1982 May;59(5):1073–1077. [PubMed] [Google Scholar]
  2. Bach J. F., Dardenne M., Pleau J. M., Bach M. A. Isolation, biochemical characteristics, and biological activity of a circulating thymic hormone in the mouse and in the human. Ann N Y Acad Sci. 1975 Feb 28;249:186–210. doi: 10.1111/j.1749-6632.1975.tb29068.x. [DOI] [PubMed] [Google Scholar]
  3. Bach J. F., Dardenne M. Studies on thymus products. II. Demonstration and characterization of a circulating thymic hormone. Immunology. 1973 Sep;25(3):353–366. [PMC free article] [PubMed] [Google Scholar]
  4. Bach J., Bardenne M., Pleau J., Rosa J. Biochemical characterisation of a serum thymic factor. Nature. 1977 Mar 3;266(5597):55–57. doi: 10.1038/266055a0. [DOI] [PubMed] [Google Scholar]
  5. Bach M. A., Beaurain G. Respective influence of extrinsic and intrinsic factors on the age-related decrease of thymic secretion. J Immunol. 1979 Jun;122(6):2505–2507. [PubMed] [Google Scholar]
  6. Bach M. A., Charreire J. Role of a circulating thymic factor in self-recognition and self-tolerance. Ann N Y Acad Sci. 1979;332:55–63. doi: 10.1111/j.1749-6632.1979.tb47097.x. [DOI] [PubMed] [Google Scholar]
  7. Bardare M., Pietrogrande M. C., Corona F., Varin E., Carnelli V., Masera G. Immune status in children with acute lymphocytic leukemia. Observations in 67 cases. Helv Paediatr Acta. 1978 Aug;33(3):241–250. [PubMed] [Google Scholar]
  8. Borella L., Green A. A., Webster R. G. Immunologic rebound after cessation of long-term chemotherapy in acute leukemia. Blood. 1972 Jul;40(1):42–51. [PubMed] [Google Scholar]
  9. Borella L., Webster R. G. The immunosuppressive effects of long-term combination chemotherapy in children with acute leukemia in remission. Cancer Res. 1971 Apr;31(4):420–426. [PubMed] [Google Scholar]
  10. Brand A., Gilmour D. G., Goldstein G. Effects of a nonapeptide FTS on lymphocyte differentiations in vitro. Nature. 1977 Oct 13;269(5629):597–598. doi: 10.1038/269597a0. [DOI] [PubMed] [Google Scholar]
  11. Dardenne M., Bach J. F., Safai B. Low serum thymic hormone levels in patients with acquired immunodeficiency syndrome. N Engl J Med. 1983 Jul 7;309(1):48–49. doi: 10.1056/NEJM198307073090112. [DOI] [PubMed] [Google Scholar]
  12. Dardenne M., Savino W., Gastinel L. N., Nabarra B., Bach J. F. Thymic dysfunction in the mutant diabetic (db/db) mouse. J Immunol. 1983 Mar;130(3):1195–1199. [PubMed] [Google Scholar]
  13. Dardenne M., Savino W., Wade S., Kaiserlian D., Lemonnier D., Bach J. F. In vivo and in vitro studies of thymulin in marginally zinc-deficient mice. Eur J Immunol. 1984 May;14(5):454–458. doi: 10.1002/eji.1830140513. [DOI] [PubMed] [Google Scholar]
  14. Davies E. G., Levinsky R. J., Butler M., Broadbent V., Pritchard J., Chessells J. Thymic hormone therapy for histiocytosis X? N Engl J Med. 1983 Aug 25;309(8):493–494. [PubMed] [Google Scholar]
  15. Davies E. G., Levinsky R. J., Butler M., Thomas R. M., Linch D. C. Lymphocyte subpopulations in primary immunodeficiency disorders. Arch Dis Child. 1983 May;58(5):346–351. doi: 10.1136/adc.58.5.346. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Fabris N., Mocchegiani E., Amadio L., Zannotti M., Licastro F., Franceschi C. Thymic hormone deficiency in normal ageing and Down's syndrome: is there a primary failure of the thymus? Lancet. 1984 May 5;1(8384):983–986. doi: 10.1016/s0140-6736(84)92325-0. [DOI] [PubMed] [Google Scholar]
  17. Hamoudi A. B., Newton W. A., Jr, Mancer K., Penn G. M. Thymic changes in histiocytosis. Am J Clin Pathol. 1982 Feb;77(2):169–173. doi: 10.1093/ajcp/77.2.169. [DOI] [PubMed] [Google Scholar]
  18. Hitzig W. H., Plüss H. J., Joller P., Pilgrim U., Tacier-Eugster H., Jakob M. Studies on the immune status of children with acute lymphocytic leukaemia. I. Early phase before and after first remission. Clin Exp Immunol. 1976 Dec;26(3):403–413. [PMC free article] [PubMed] [Google Scholar]
  19. Hitzig W. H., Plüss H. J., Joller P., Pilgrim U., Tacier-Eugster H., Jakob M. Studies on the immune status of children with acute lymphocytic leukaemia. II. In remission with and without cytostatic treatment. Clin Exp Immunol. 1976 Dec;26(3):414–418. [PMC free article] [PubMed] [Google Scholar]
  20. Hughes W. T. Fatal infections in childhood leukemia. Am J Dis Child. 1971 Oct;122(4):283–287. doi: 10.1001/archpedi.1971.02110040067003. [DOI] [PubMed] [Google Scholar]
  21. Incefy G. S., Dardenne M., Pahwa S., Grimes E., Pahwa R. N., Smithwick E., O'Reilly R., Good R. A. Thymic activity in severe combined immunodeficiency diseases. Proc Natl Acad Sci U S A. 1977 Mar;74(3):1250–1253. doi: 10.1073/pnas.74.3.1250. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Iwata T., Incefy G. S., Tanaka T., Fernandes G., Menendez-Botet C. J., Pih K., Good R. A. Circulating thymic hormone levels in zinc deficiency. Cell Immunol. 1979 Sep 15;47(1):100–105. doi: 10.1016/0008-8749(79)90318-6. [DOI] [PubMed] [Google Scholar]
  23. Kersey J., Nesbit M., Hallgren H., Sabad A., Yunis E., Gajl-Peczalska K. Evidence for origin of certain childhood acute lymphoblastic leukemias and lymphomas in thymus-derived lymphocytes. Cancer. 1975 Oct;36(4):1348–1352. doi: 10.1002/1097-0142(197510)36:4<1348::aid-cncr2820360424>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  24. Levai J. S., Utermohlen V. The effect of a human plasma thymic factor on human peripheral blood mononuclear cell subpopulations. Clin Immunol Immunopathol. 1983 Jun;27(3):433–443. doi: 10.1016/0090-1229(83)90095-8. [DOI] [PubMed] [Google Scholar]
  25. Osband M. E., Lipton J. M., Lavin P., Levey R., Vawter G., Greenberger J. S., McCaffrey R. P., Parkman R. Histiocytosis-X. N Engl J Med. 1981 Jan 15;304(3):146–153. doi: 10.1056/NEJM198101153040304. [DOI] [PubMed] [Google Scholar]
  26. Pasino M., Vadalà C. R., De Bernardi B., Comelli A., Mori P. G., Dini G., Bisogni M. C., Tonini G. P., Massimo L. Immunological evaluation of 22 patients with acute lymphoblastic leukemia off-therapy. A longitudinal follow-up. Helv Paediatr Acta. 1981 Feb;36(1):69–80. [PubMed] [Google Scholar]
  27. Rappaport H., Machover D., Bearman R., Nathwani B., Lemaigre M. G., Santelli G., Verley J. M., Canon C., Mathe G. Histopathology of the thymus of patients with acute lymphoblastic leukemia and lymphoblastic lymphoma in complete clinical remission. Blood. 1981 Oct;58(4):852–855. [PubMed] [Google Scholar]
  28. Simone J. V., Holland E., Johnson W. Fatalities during remission of childhood leukemia. Blood. 1972 Jun;39(6):759–770. [PubMed] [Google Scholar]
  29. Thomas E. D., Buckner C. D., Clift R. A., Fefer A., Johnson F. L., Neiman P. E., Sale G. E., Sanders J. E., Singer J. W., Shulman H. Marrow transplantation for acute nonlymphoblastic leukemia in first remission. N Engl J Med. 1979 Sep 13;301(11):597–599. doi: 10.1056/NEJM197909133011109. [DOI] [PubMed] [Google Scholar]
  30. Twomey J. J., Lewis V. M., Ford R., Goldstein G. An inhibitor of thymic hormone activity in serum from patients with lymphoblastic leukemia. Am J Med. 1980 Mar;68(3):377–380. doi: 10.1016/0002-9343(80)90106-0. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES